USL311 is an orally active CXCR4-specific antagonist that inhibits the binding of stromal cell-derived factor-1 (SDF-1/CXCL12) to CXCR4[1-2]. Chemokine C-X-C receptor 4 (CXCR4) is a key axis of normal development and immunity and is often aberrantly expressed in various cancer types[3]. USL311 has anticancer effects, such as in glioblastoma, and can be used in combination with lomustine to treat patients with advanced solid tumors and recurrent GBM[2].
References:
[1]. Peter Richardson. Usl-311 for use in the treatment of cancer. WO2018162924A1.
[2]. Rueda A, Serna N, Mangues R, et al. Targeting the chemokine receptor CXCR4 for cancer therapies[J]. Biomarker Research, 2025, 13(1): 68.
[3]. MacLean M R, Walker O L, Arun R P, et al. Informed by cancer stem cells of solid tumors: advances in treatments targeting tumor-promoting factors and pathways[J]. International journal of molecular sciences, 2024, 25(7): 4102.
USL311是一种具有口服活性的CXCR4特异性拮抗剂，能够抑制基质细胞源性因子-1 (SDF-1/CXCL12) 与 CXCR4的结合[1-2]。趋化因子C-X-C受体4（CXCR4）是正常发育和免疫的关键轴，在多种癌症类型中往往异常表达[3]。USL311具有抗癌作用，如胶质母细胞瘤，能够与lomustine联合治疗晚期实体肿瘤和复发性GBM患者[2]。